| abstract |
The present invention, corticotropin releasing factor subtype -2 (CRF 2) an antisense oligonucleotide against the mRNA of the receptor, in vivo CNS substantially oligonucleotide decreases and gene expression CRF 2 receptor expression in rodent brain The use of antisense oligonucleotides in research and the treatment of a wide range of psychiatric disorders, including anxiety, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, phobia and depression. |